Statins are one of the key drugs in the treatment of cardiology patients. They lower LDL cholesterol levels, thereby reducing the risk of acute cardiovascular events. Statins are among the best studied drugs, and have been proven to be effective and safe in the treatment of dyslipidemia. Data presented in studies on the prevalence of statin intolerance (SI) varies widely, according to some studies, statin tolerance is the same as placebo, however, this is a common problem in clinical practice. The most common reported symptoms of SI include muscle pain. Patients are often afraid of starting satin treatment because of possible side effects. The appearance of myopathy in patients results in their discontinuation of therapy, which results in increased cardiovascular risk. In order to minimize the risk of SI, particularly statin-associated muscular pain (SI), a key role is played by discussion with the patient, exclusion of nocebo effects, identification of risk factors, dose modification and possible discontinuation of the drug. The purpose of this paper is to review the problem of the most common of the adverse effects of statins- myopathy, in terms of incidence, probable cause, and recommended treatment of patients.

Background: Status epilepticus (SE) is a serious neurological disease which manifests itself as prolonged seizures which last more than 5 minutes and between such episodes patients do not regain consciousness. Not only can it result in cognitive defects, but also in brain damage or even death. It is commonly known that one of the causes can be inflammatory process, but here we will focus on inflammation as a result in new onset refractory status epilepticus and related to this, new promising forms of SE treatment. Particular emphasis has been focused on new-onset refractory status epilepticus (NORSE). Methods: Based on public research databases, drugs with anti-inflammatory activity – commonly used in different spheres of medicine – have been reviewed as potentially treating status epilepticus. Results: There is seizable clinical research suggesting that drugs that decrease inflammatory process might be effective in terminating status epilepticus. Conclusion: There is growing evidence that adding anti-inflammatory drugs to basic antiepileptic treatment enhances the efficiency of the therapeutic process, with special potential in NORSE cases

Introduction and purposeSoy as a rich source of isoflavones has become a focus of interest because of its positive health benefits on numerous diseases, particularly hormone-related cancers. The aim of this study was to present the current state of knowledge on the role of soy in the development of breast, ovarian, endometrial, and prostate gland cancer.A brief description of the state of knowledgeSoy components reduce inflammation, stress oxidative and inhibit proliferation of breast, ovarian, endometrial, and prostate cancer cells. Isoflavones such as genistein, daidzein, S-equol via activation of estrogen receptors, inhibit aromatase synthesis and may decrease the risk of estrogen-dependent cancers. Moreover, soy food products have the potential toregulate molecular pathways of AR and reduce testosterone levels. It leads to a reduced risk of prostate cancer. Furthermore, increased consumption of soy protein and isoflavones decreased the risk of mortality from cancers.ConclusionsSoy foods and their isoflavones are associated with reduced carcinogenesis. A higher amount of soy intake can have positive benefits for prevention of cancers including breast, prostate gland, endometrial and ovarian cancer.

Vitamin D is traditionally associated with the regulation of mineral metabolism and bone homeostasis, and its deficiency is the cause of diseases such as osteoporosis or osteomalacia. However, numerous studies in recent years suggest that thanks to the common expression of the vitamin D receptor (VDR) on the cells of the body and the related additional anti-inflammatory, immunomodulating, antioxidant, anti-fibrotic vitamin D effects, it may play a role in the development and progress of autoimmune diseases and tumors. The collected data suggest that low vitamin D levels correlate with the occurrence of autoimmune diseases of the thyroid gland and that there is a significant correlation between 25(OH)D and anti-TPO or anti-Tg levels. However, these data are inconclusive and further research is needed to confirm this relationship and determine whether lowered vitamin D titer is the cause or rather the consequence of autoimmune thyroid disorders, and whether vitamin D supplementation could prove to be an effective prophylaxis and treatment.